Ballerup, Denmark and Redwood City, CA, USA – September 3, 2020 – Norlase, an emerging global ophthalmic medical device company developing next-generation laser solutions, is thrilled to announce that it has appointed Taoufiq (TJ) Jellal to the position of Vice President of Global Distribution. Mr. Jellal brings over thirty years of ophthalmic device experience to Norlase, having previously held regional and global sales and management positions at successful ophthalmic companies, including Allergan, Alcon, and laser manufacturer IRIDEX.
“Norlase is proud of our deeply committed leadership team who has proven that they are passionate about providing physicians with the smartest solutions for improving patient care,” said Oliver Hvidt, Norlase CEO and President. “Taoufiq joins us at a pivotal time of growth and expansion. His many years of executive leadership and experience in bringing ophthalmic devices to market, and his outstanding ability to deliver bottom and top line results makes him an excellent choice to guide future growth.”
Mr. Jellal has also held leadership roles in product management, marketing, and distribution. He has helped launch countless products, managed large distributor networks, and has an impressive track record of increasing company growth and sales. Taoufiq was formerly with Centricity Vision Inc., where he was the EURMEA Vice President of Sales and Marketing.
“Since the start of my career in ophthalmology back in 1989, I’ve had the great fortune of supporting the creation and growth of major markets in Europe, the Middle East and Africa for many companies,” commented Taoufiq Jellal, Norlase Vice President of Global Distribution. “I’m so excited to join the Norlase team and for the great milestones they have achieved with FDA clearance and CE Mark approval for the LEAF Green Laser. I’m certain that it will achieve global commercial success by becoming a major player and offering an innovative technology that helps eye doctors treat patients with retina and glaucoma disorders. The cost savings related to fiber failures, a voice command option, the portability of the laser and affordable price point will make LEAF the laser of choice for many ophthalmologists around the world.”
Norlase develops next-generation laser solutions for the treatment of retina and glaucoma diseases. Founded in Denmark, Norlase is comprised of worldwide industry experts in ophthalmology, laser technology, medical device development, and customer care. Norlase is on a mission to improve practice efficiency, patient care and physician convenience for ophthalmologists worldwide. Norlase entered the United States ophthalmic market with LEAF, a new laser photocoagulator that’s 10X smaller than existing systems and mounts directly on the slit-lamp.